Obesity Reviews肥胖评论
Obesity Reviews(英文缩写 OBES REV),ISSN 1467-7881,eISSN 1467-789X,中文译名:肥胖评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 10.867 | Q1 |
| 2022 | 8.900 | Q1 |
| 2023 | 8.000 | Q1 |
| 2024 | 7.400 | Q1 |
| 2025 | 7.600 | Q1 |
Obesity Reviews 最新收录文献
-
1. Incretin-Based Therapy in Patients with Malignancy and Obesity or Type 2 Diabetes. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF), and Italian Society of Obesity (SIO) Position Paper.
1. 基于肠促胰素的治疗在恶性肿瘤合并肥胖或2型糖尿病患者中的应用。意大利肿瘤内科协会（AIOM）、意大利糖尿病医师协会（AMD）、意大利糖尿病学会（SID）、意大利内分泌学会（SIE）、意大利药理学学会（SIF）和意大利肥胖学会（SIO）的立场文件PMID:期刊:日期:2026-10-01Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as pivotal agents in the treatment of type 2 diabetes (T2D) and obesity, with well-established metabolic and cardiovascular benefits that translate into improvement in quality of life and life expectancy. While a potential benefit may also be hypothesized in patients with metabolic disorders and malignancy, robust clinical evidence is still lacking. In recent years, attention has turned to their potential impact on cancer risk, although current evidence remains limited and, in some cases, conflicting. Several biological pathways, such as improvements in insulin sensitivity, reductions in chronic inflammation, modulation of cellular signaling, and changes in the tumor microenvironment, have been proposed as possible mechanisms through which GLP-1RAs might influence cancer development or progression. However, available data derive from preclinical or observational studies, and high-quality prospective clinical evidence is still lacking. While some reports suggest possible protective associations in specific cancer types, others raise concerns about potential risks, particularly in hormonally sensitive or receptor-expressing tissues. This position paper synthesizes available data on the oncologic safety and potential antitumor effects of GLP-1RAs, highlights key knowledge gaps, and discusses clinical implications, underscoring the need for further research to clarify their role in cancer prevention and treatment.
-
2. The Intertwined Epidemics of Obesity and Obstructive Sleep Apnea: A Comprehensive Analysis.
2. 肥胖与阻塞性睡眠呼吸暂停的流行交织：一项综合分析PMID:期刊:日期:2026-09-23The escalating global prevalence of both obesity and obstructive sleep apnea (OSA) represents a major public health challenge due to their combined impact on individual health outcomes and healthcare infrastructure. This review provides an analytical evaluation of the complex, bidirectional relationship between these conditions. Evidence demonstrates that OSA prevalence rises markedly across progressive body mass index (BMI) categories, reaching up to 90% in individuals with Class III obesity. This association is driven by mechanical mechanisms-such as upper airway pharyngeal fat accumulation and reduced lung volumes-as well as systemic metabolic inflammation and cellular dysfunction. Conversely, OSA promotes weight gain and metabolic dysregulation through sleep fragmentation, excessive daytime somnolence, and disruption of appetite-regulating hormones (elevated ghrelin and leptin resistance). Interventions yielding weight loss, including structured lifestyle modifications, novel glucagon-like peptide-1 (GLP-1) receptor agonists, and bariatric surgery, demonstrate significant reductions in the apnea-hypopnea index (AHI) and cardiometabolic risk. Given the high co-occurrence and severe cardiovascular risk associated with untreated OSA, routine clinical screening and integrated multidisciplinary management strategies targeting both conditions are essential.
-
3. The Lived Experience of Children and Adults with Overweight or Obesity Engaging in Weight Management Treatments: An Umbrella Scoping Review with Narrative Synthesis.
PMID:期刊:日期:2026-09-23Understanding the lived experience of people with overweight or obesity is essential to ensure that interventions are free from weight stigma, avoid adverse consequences including eating disorder pathology, increase engagement, and promote culturally sensitive approaches to care. We aimed to synthesize published review evidence of the lived experience of people living with overweight and obesity engaging in weight management interventions. Database searches using defined inclusion criteria were undertaken in Ovid MEDLINE, APA PsycINFO via EBSCOHost, CINAHL Complete via EBSCOHost, and Cochrane Library. After screening and data extraction, thematic synthesis was undertaken using the Copilot large language model and verified by a researcher who had detailed knowledge of all included reviews. The database searches identified 4183 studies, with 38 reviews meeting the inclusion criteria. Supportive networks (including familial, social, healthcare, and employment) were key to initiation, engagement and maintenance of weight loss across all age groups and interventions. Intervention design and delivery approaches that were accessible, individually tailored, collaborative, age-appropriate, culturally sensitive, and free from judgment and stigma were key to sustained engagement with programs. This umbrella review identified emotional, healthcare, cultural, and societal implications for the weight stigma and bias described by participants in the current literature. By actively working to reduce weight bias and stigma in clinical practice, research, and guideline development, healthcare professionals, and academics can foster more equitable and effective weight management interventions that prioritize the long-term health of people living with overweight or obesity.
-
4. Decoding Obesity Through the Lens of Adipose Tissue Inflammatory Regulation: A Comparative Study of Obesity Subtypes.
4. 从脂肪组织炎症调控视角解读肥胖：肥胖亚型的比较研究PMID:期刊:日期:2026-09-23Obesity is increasingly recognized as a heterogeneous condition rather than a single disease entity. Although body mass index remains widely used in clinical practice, it does not adequately reflect differences in fat distribution, metabolic status, inflammatory activity, or body composition. As a result, individuals with similar body mass index values may have markedly different cardiometabolic risk profiles and clinical trajectories. This review examines four clinically relevant obesity-related phenotypes, namely metabolically healthy obesity, metabolically unhealthy obesity, metabolically obese normal weight, and sarcopenic obesity, within an integrated framework linking inflammation, metabolism, and structural tissue remodeling. Across these phenotypes, adipose dysfunction and chronic low-grade inflammation represent a common biological background. However, important differences arise from the extent to which inflammatory stress is buffered, amplified, or coupled to maladaptive remodeling in adipose tissue and skeletal muscle. Metabolically healthy obesity is characterized by relatively preserved metabolic function and a more favorable fat distribution, although this state is often unstable over time. Metabolically unhealthy obesity reflects overt metabolic decompensation driven by visceral adiposity, ectopic fat deposition, and amplified inflammatory signaling. Metabolically obese normal weight highlights concealed metabolic risk despite normal body weight, whereas sarcopenic obesity represents the coexistence of excess adiposity with impaired muscle mass and function. Taken together, these phenotypes are best viewed as dynamic and partially overlapping states. A phenotype-informed approach may improve risk stratification and support more precise strategies for prevention and treatment.
-
5. Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction.
5. 模糊概念提出八十年后：对异位脂肪和代谢功能障碍认识的进展PMID:期刊:日期:2026-09-23The distribution of adipose tissue is a key determinant of obesity-related disease risk. When the capacity of subcutaneous adipose tissue to safely store energy is exceeded, lipid overflow into visceral depots occurs, increasing free fatty acid flux, promoting insulin resistance, and triggering chronic low-grade inflammation. More than 80 years ago, the physician Jean Vague recognized the association between android (central) obesity and cardiometabolic disease; subsequent advances from imaging technologies have expanded this framework to include ectopic fat accumulation within non-adipose organs. Ectopic fat deposition in the liver, pancreas, heart, kidneys, skeletal muscle, and upper airway contributes to organ-specific dysfunction through mechanisms including lipotoxicity, adipokine dysregulation, oxidative stress, and local inflammatory signaling. This review summarizes the evidence linking visceral and ectopic fat to metabolic dysfunction-associated steatotic liver disease and steatohepatitis, type 2 diabetes, cardiovascular and renal disease, sarcopenic obesity, and obstructive sleep apnea. Importantly, visceral and ectopic fat depots are modifiable. Lifestyle-induced energy deficit, incretin-based pharmacotherapy, and metabolic bariatric surgery reduce visceral and ectopic fat and improve glycemic control, liver fat content, cardiovascular risk factors, physical function, and sleep-disordered breathing. Incorporating ectopic fat characterization into clinical practice may enhance risk stratification and support more personalized management of obesity phenotypes.
-
6. Trends and Approaches in Obesity and Overweight Research Focused on White Adipose Tissue and Browning: A Bibliometric Study.
6. 以白色脂肪组织与棕色化为重点的肥胖和超重研究趋势与方法：一项文献计量学研究PMID:期刊:日期:2026-09-21The global rise in obesity has intensified scientific interest in adipose tissue biology, particularly the mechanisms underlying white adipose tissue (WAT) browning. This bibliometric study mapped the evolution, structure, and emerging directions of research on obesity, overweight, and WAT browning from 2011 to May 2025. Records were retrieved from Web of Science, Scopus, and PubMed and analyzed using VOSviewer, Bibliometrix, and Biblioshiny. A total of 2106 publications were identified, with a notable surge in output over the last decade. The United States, China, and several European countries emerged as leading contributors in terms of publication volume and citations. Influential journals were identified, highlighting interdisciplinary collaboration across molecular biology, endocrinology, and metabolic research. Keyword co-occurrence and trend-topic analyses identified thermogenesis, mitochondrial activity, transcriptional regulation, and adipocyte differentiation as central themes, whereas more recent research has shifted toward omics-based approaches, autophagy, gut microbiota, extracellular vesicles, immune regulation, and neuroendocrine pathways. Despite major mechanistic advances, the literature remains predominantly preclinical, and the contribution of beige adipocytes to whole-body energy expenditure in humans appears modest. Overall, the field has evolved from the identification of thermogenic adipocytes toward a more integrated view of adipose tissue plasticity and interorgan communication, although substantial challenges remain for clinical translation and long-term validation.
-
7. Effect of Medium Chain Fatty Acids on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.
7. 中链脂肪酸对超重和肥胖个体身体成分的影响：系统综述与荟萃分析PMID:期刊:日期:2026-09-18To evaluate the effects of medium-chain triacylglycerol (MCT) intake on the body composition of individuals with overweight and obesity through a systematic review and meta-analysis of randomized controlled trials (RCTs). PubMed, Cochrane Library, and Embase databases were searched until January 2026. The primary outcome was the change in fat mass (FM) between the MCT intake and control groups; secondary outcomes included body weight (BW), waist circumference (WC), and lean mass (LM). Pooled effect sizes were estimated using random-effects models, and certainty was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). RoB-2 was used for assessing risk of bias. Seven RCTs (N = 346) were included in this study. MCT intake significantly reduced FM (SMD: -0.42; 95% CI: -0.67 to -0.17), BW (SMD: -0.41; 95% CI: -0.64 to -0.18), and WC (SMD: -0.42; 95% CI: -0.69 to -0.14) compared to controls, with no significant effect on LM. Heterogeneity was low (I = 0%), although the certainty of the evidence was low. Sensitivity analyses for BMI ≧ 25 kg/m confirmed these findings. Adverse events associated with MCT intake are rare and well-tolerated. MCT intake effectively and safely reduced body fat and waist circumference while preserving lean mass, suggesting its value in obesity management.
-
8. Effectiveness of Mobile Application-Based Multimodal Behavioral Interventions on Weight Loss in Obesity: A Systematic Review and Meta-Analysis.
8. 基于移动应用的多模式行为干预对肥胖减肥的有效性：系统综述和荟萃分析PMID:期刊:日期:2026-09-07Healthcare systems face increasing demands in chronic disease management such as obesity. Mobile applications offer scalable tools for weight management, ranging from simple trackers to prescribable digital therapeutics. This review evaluates the effectiveness of fully remote, app-based interventions using a multimodal approach for weight loss in adults with obesity. Complying with international guidelines, these interventions combine behavior change strategies for diet, physical activity, and/or psychosocial education. A systematic literature search was performed. Eligible studies were assessed using the Cochrane Risk of Bias Tool 2 and the Grading of Recommendations, Assessment, Development and Evaluation approach for certainty of evidence. A meta-analysis was performed for body weight outcomes. Twelve randomized controlled trials and five systematic reviews were included, reporting changes in body weight or body mass index. The standardized mean difference of body weight changes at the end of intervention was -0.50 (95% confidence interval: -0.77, -0.22), corresponding to a mean difference of -2.61 kg (-4.45, -0.78). Heterogeneity was substantial (I = 79.2%; p < 0.0001). Fully remote, app-based interventions show moderate weight loss with promising potential in obesity management. However, heterogeneity between studies highlights the need for further research into potential factors with a significant influence on the results.
-
9. Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan.
9. 肥胖中的微生物组和代谢组学：终身理解和干预的进展PMID:期刊:日期:2026-09-02Obesity arises from intertwined and reciprocal diet-microbiome-host pathways that reshape energy balance, insulin sensitivity, and inflammation. This review synthesizes mechanistic links between microbial functions and metabolic control, charts lifestyle-related lifecourse dynamics from birth to older age, examines how GLP-1-based therapies may perturb gut ecology and metabolite output and surveys AI/ML frameworks for multi-omics integration. Plant-based, fiber-rich dietary patterns generally enrich saccharolytic guilds, boost SCFAs production, and modulate bile acid signaling, whereas Westernized patterns favor bile-tolerant, amino acid-fermenting consortia and proinflammatory metabolites. Preclinical data suggest that incretin-based therapies remodel the microbiome-metabolome axis, but human causal mediation remains unproven and observed changes may partly reflect weight loss or metabolic improvement. Function-centered metrics outperform phylum-level ratios for translation. Harmonized longitudinal cohorts and explainable ML-derived microbial and metabolomic signatures are now pivotal to identify responder subtypes and actionable microbe-metabolite targets, enabling precision nutrition alongside pharmacotherapy across the lifespan.
-
10. Epigenomic Cascades Across Organs in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Therapeutic Horizons.
10. 代谢功能障碍相关脂肪性肝病中跨器官的表观基因组级联反应：新的治疗前景PMID:期刊:日期:2026-08-31Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide, affecting approximately one-third of the population and increasing the risk of severe hepatic and cardiovascular complications. Growing evidence indicates that MASLD is a systemic disease in which epigenetic changes-including DNA and RNA methylation as well as histone modifications-drive its progression by integrating metabolic and inflammatory signals across organs. This review introduces the concept of "networked epigenome cascades" and highlights how epigenetic alterations in extrahepatic metabolic organs contribute to insulin resistance (IR) and systemic inflammation. MASLD is thereby reframed as a disorder of systemic epigenomic miscommunication rather than a liver-only disease. We further discuss preclinical and emerging interventions, with an emphasis on natural compounds that modulate epigenomic regulation, while noting the uncertainties that remain regarding their translational potential for MASLD. By positioning the epigenome as a central mechanism, this review underscores its promise for biomarker development and mechanistically targeted interventions, although robust validation in humans is still required.